MX2016004286A - Biomarcadores de cancer y usos de los mismos. - Google Patents

Biomarcadores de cancer y usos de los mismos.

Info

Publication number
MX2016004286A
MX2016004286A MX2016004286A MX2016004286A MX2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A
Authority
MX
Mexico
Prior art keywords
her2
specific binding
binding member
domain
cancer biomarkers
Prior art date
Application number
MX2016004286A
Other languages
English (en)
Inventor
Batey Sarah
Leung Kinmei
Sun Haijun
Rowland Robert
Original Assignee
F-Star Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnology Ltd filed Critical F-Star Biotechnology Ltd
Publication of MX2016004286A publication Critical patent/MX2016004286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de un número de copias de genes del Receptor 2 del Factor de Crecimiento Epidérmico Humano (HER2) y a niveles de ARNm de HER2 como biomarcadores para identificar cánceres que responderán al tratamiento con un miembro de unión específica que comprende un sitio de unión a antígeno de HER2 modificado por ingeniería genética en una región de bucle estructural de un dominio constante, por ejemplo el dominio CH3, del miembro de unión específica y miembros de unión específica que compiten con tal miembro de unión para su unión a HER2.
MX2016004286A 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos. MX2016004286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof
PCT/GB2014/052994 WO2015049537A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX2016004286A true MX2016004286A (es) 2017-01-18

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004286A MX2016004286A (es) 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos.

Country Status (21)

Country Link
US (1) US20160289336A1 (es)
EP (1) EP3052647B1 (es)
JP (1) JP6449308B2 (es)
KR (1) KR20160092992A (es)
CN (1) CN105722997A (es)
AU (1) AU2014330942A1 (es)
BR (1) BR112016007348A2 (es)
CA (1) CA2925186A1 (es)
CL (1) CL2016000777A1 (es)
DK (1) DK3052647T3 (es)
EA (1) EA201690450A1 (es)
ES (1) ES2687783T3 (es)
GB (1) GB201317622D0 (es)
HK (1) HK1221746A1 (es)
HR (1) HRP20181566T1 (es)
IL (1) IL244510A0 (es)
LT (1) LT3052647T (es)
MX (1) MX2016004286A (es)
PE (1) PE20160950A1 (es)
SG (1) SG11201602605TA (es)
WO (1) WO2015049537A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1772465E (pt) 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CN101802006B (zh) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2016162505A1 (en) * 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) * 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
KR20200139219A (ko) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 항-trem-1 항체 및 이의 용도
CN112584862A (zh) * 2018-05-17 2021-03-30 伊米若梅有限公司 Ch3结构域表位标签
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1772465E (pt) * 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
CN101802006B (zh) * 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2761280A1 (en) * 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
LT3052647T (lt) 2018-10-25
DK3052647T3 (en) 2018-10-22
IL244510A0 (en) 2016-04-21
US20160289336A1 (en) 2016-10-06
EP3052647B1 (en) 2018-07-11
SG11201602605TA (en) 2016-04-28
HK1221746A1 (zh) 2017-06-09
BR112016007348A2 (pt) 2018-01-23
KR20160092992A (ko) 2016-08-05
CA2925186A1 (en) 2015-04-09
EP3052647A1 (en) 2016-08-10
JP2016533395A (ja) 2016-10-27
CL2016000777A1 (es) 2017-02-17
JP6449308B2 (ja) 2019-01-09
EA201690450A1 (ru) 2016-10-31
HRP20181566T1 (hr) 2018-11-30
GB201317622D0 (en) 2013-11-20
ES2687783T3 (es) 2018-10-29
AU2014330942A1 (en) 2016-05-19
WO2015049537A1 (en) 2015-04-09
CN105722997A (zh) 2016-06-29
PE20160950A1 (es) 2016-10-02

Similar Documents

Publication Publication Date Title
MX2016004286A (es) Biomarcadores de cancer y usos de los mismos.
PH12018501473A1 (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12017500890A1 (en) Antibody drug conjugates
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
GEP20217331B (en) Anti-tigit antibodies
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
SG10201908558WA (en) Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2011010955A (es) Terapia complementaria contra el cancer.
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
NZ601588A (en) Methods for treating breast cancer
NZ611785A (en) Anti-notch1 antibodies
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
IN2014DN09717A (es)
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
NZ730247A (en) Antibodies to ticagrelor and methods of use
NZ625758A (en) Method for treating breast cancer
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.